Form 4: Castle Biosciences Director Daniel Bradbury Sells Shares Under 10b5-1 Plan

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on May 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Bradbury, a director at Castle Biosciences, sold shares of the company's common stock on May 6, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 23, 2023.
• He sold 7,393 shares directly at a weighted-average price of $24.64.
• Additionally, sales were made from holdings by BioBrit, LLC (7,963 shares), Daniel Bradbury Irrevocable Descendant's Trust (7,967 shares), and Annette Bradbury Irrevocable Descendant's Trust (4,655 shares).
• Following these transactions, Bradbury directly owns 4,655 shares and indirectly owns 35,123 shares through BioBrit, LLC, 9,981 shares through the Daniel Bradbury Irrevocable Descendant's Trust, and 9,981 shares through the Annette Bradbury Irrevocable Descendant's Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in stock price, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates